

70640

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C12N 15/00, C07G 17/00 C07H 21/04, C07K 15/12, 13/00 C07K 7/08, C12N 9/10, 1/20 G01N 33/543	A1	(11) International Publication Number: WO 88/04689 (43) International Publication Date: 30 June 1988 (30.06.88)
(21) International Application Number: PCT/AU87/00427 (22) International Filing Date: 16 December 1987 (16.12.87)	(74) Agents: SLATTERY, John, Michael et al.; Davies & Collison, 1 Little Collins Street, Melbourne, VIC 3000 (AU).	
(31) Priority Application Number: PH 9523 (32) Priority Date: 16 December 1986 (16.12.86) (33) Priority Country: AU	(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.	
(71) Applicant (for all designated States except US): AM-RAD CORPORATION LIMITED [AU/AU]; Unit 6, 663 Victoria Street, Abbotsford, VIC 3067 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only) : COPPEL, Ross, Leon [AU/AU]; 6 Mercer Road, Armadale, VIC 3143 (AU). GERSHWIN, Merrill, Eric [US/US]; 1102 Kent Drive, Davis, CA 95616 (US).	Published <i>With international search report.</i>	

(54) Title: PRIMARY BILIARY CIRRHOSIS AUTOANTIGEN

(57) Abstract

A synthetic peptide or polypeptide displaying the antigenicity of all or a portion of the 70kd mitochondrial autoantigen of primary biliary cirrhosis, or an antigenically active fragment thereof, is produced by recombinant DNA techniques. The synthetic peptide or polypeptide, or fragment, may be used in the treatment of patients or in diagnostic tests, particularly for the detection of anti-mitochondrial antibody in a serum sample.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	FR France	ML Mali
AU Australia	GA Gabon	MR Mauritania
BB Barbados	GB United Kingdom	MW Malawi
BE Belgium	HU Hungary	NL Netherlands
BG Bulgaria	IT Italy	NO Norway
BJ Benin	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroon	LU Luxembourg	TD Chad
DE Germany, Federal Republic of	MC Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland		

PRIMARY BILIARY CIRRHOSIS AUTOANTIGEN

This invention relates to the identification, cloning and expression of an auto-antigen which is recognised as a target in the characteristic autoantibody response in primary biliary cirrhosis (PBC), and to the use of this protein, fragments thereof or fused polypeptides containing the protein or fragments thereof in diagnostic tests for PBC, and in treatment of patients suffering from PBC.

Primary biliary cirrhosis (PBC) is a chronic disease characterised by progressive inflammatory obliteration of the intrahepatic bile ducts. The disease is marked by an autoantibody response to mitochondria¹⁻⁴, originally identified using immunofluorescence⁵. With the recent use of immunoblotting, specific proteins have been

recognized as targets of the anti-mitochondrial antibodies (AMA) of PBC^{2,6,7}. In particular, serum antibodies to a 70 kilodalton (kd) protein have been found in greater than 95% of patients with PBC but not in 5 patients with other autoimmune liver diseases,^{2,8}; two other proteins of 45 and 39kd are less frequently detected in PBC sera^{1,2,9}. The identity of each of these autoantigens has been unknown, as is the relationship of these antigens to the pathogenesis of the disease.

10 However, the 70kd antigen is highly conserved in evolution, being present in mammals, yeast and bacteria¹⁰ and it is therefore believed to have an important structural or biological function².

Despite the paucity of data on mechanisms of 15 anti-mitochondrial antibody formation, by enzyme-linked immunosorbent assay (ELISA), clinically more than 95% of patients with PBC can be found to have such anti-mitochondrial antibodies^{2,6}. When crude mitochondrial antigen preparations are used, subjects with 20 a variety of diseases, including patients with liver diseases other than PBC, certain connective tissue diseases, and drug reactions, and occasionally even healthy individuals, can also be demonstrated to have antibodies to mitochondria. Accordingly, assays using 25 such crude preparations are unable to provide specific diagnosis of PBC. By way of example, German Patent Publication No. 3,237,602 discloses an ELISA for detection and determination of antimitochondrial antibodies in serum using a crude mitochondrial antigen preparation. The lack 30 of specificity of the assay is evident from the suggested use of the assay in the specific diagnosis of disorders such as PBC as well as the cholestatic form of chronic active hepatitis, syphilis (II), drug-induced pseudo lupus erythematoses syndrome, certain primary non-hepatic

immunopathies, iproniazid-induced hepatitis and side effects of certain medicaments such as beta-receptor blockers. By more vigorous isolation of mitochondrial membranes, the problem of antigenic heterogeneity becomes clearer and has 5 led to definitions of specific mitochondrial antigens based on trypsin sensitivity and location of antigens within inner vs outer mitochondrial membranes. Notwithstanding this, however, the diagnosis of PBC still relies heavily on the demonstration of anti-mitochondrial 10 antibodies by the relatively insensitive procedure of immunofluorescence or by more sensitive, but still relatively nonspecific, methods, including complement fixation, ELISA, and immunoprecipitation²³⁻²⁸.

The present invention is based on the 15 identification of a cDNA clone derived from a rat liver gene expression library that expresses the 70kd mitochondrial autoantigen of PBC, (called M2 by some groups of investigators^{1,9}) and on sequence determination thereof. The sequence is encoded by nuclear 20 and not mitochondrial DNA.

The present invention thus provides the basis of an extremely sensitive and specific diagnostic ELISA for anti-70kd antibodies found in PBC.

According to a first aspect of the present 25 invention, there is provided a DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of the base sequence coding for the 70kd mitochondrial autoantigen of primary biliary cirrhosis (PBC), or an antigenically active fragment thereof.

30 Preferably, the DNA molecule in accordance with this aspect of the invention is characterised by at least a portion thereof comprising a base sequence substantially as shown in Figure 6, or a fragment thereof.

In another aspect, this invention provides a

recombinant DNA molecule comprising a nucleotide sequence as described above, operatively linked to an expression control sequence. Such a recombinant DNA molecule may for example comprise an expression vector such as a 5 bacteriophage or plasmid, or a host cell such as a bacterium or other microorganism transformed therewith.

In yet another aspect of this invention there is provided a synthetic peptide or polypeptide displaying the antigenicity of all or a portion of the 70kd mitochondrial 10 autoantigen of primary biliary cirrhosis, or an antigenically active fragment thereof.

Preferably, the synthetic peptide or polypeptide of this aspect of the invention is characterised by at least a portion thereof comprising an amino acid sequence 15 substantially as shown in Figure 6 or Figure 8, or an antigenically active fragment thereof.

Such a synthetic peptide or polypeptide may, for example, be prepared by expression of a host cell transformed with a recombinant DNA molecule as broadly 20 described above, either as a fused polypeptide or directly. Alternatively, it may be prepared by chemical synthesis, such as by the well-known Merrifield solid-phase synthesis procedure.

The present invention extends to the synthetic 25 peptide corresponding to the entire 70kd autoantigen, and to nucleotide sequences coding for the entire autoantigen, as well as to fragments thereof. By way of example, one such fragment is the fragment encoded by nucleotides 76-679 of Figure 6. This fragment of approximately 200 30 residues is capable of adsorbing out of a patient serum all antibodies directed against the native autoantigen. Within this fragment is a 20 residue fragment of amino acid sequence:

A E I E T D K A T I G F E V Q E E G Y L

which has been demonstrated to have substantial reactivity with autoantibodies. This fragment is common to the sequences of both Figure 6 and Figure 8. The present invention therefore extends to the use of antigenically active fragments such as these, as well as to the use of the entire autoantigen, in diagnostic assays.

The present invention also extends to the use of the synthetic peptide or polypeptide, or fragment, of this invention as an antigen in a diagnostic test for PBC by detection or determination of the titre of antimitochondrial antibody in a patient's serum, for example using ELISA or RIA technology or an agglutination assay using antigen-coated beads or the like. The invention also extends to use of the synthetic peptide or polypeptide, or fragment, in the treatment of patients. In this latter aspect, such methods of treatment include the use of the synthetic antigen, as an adsorbent to remove PBC antibodies or reactive cells from a patient, as well as the use of these active components in direct administration to a patient as a desensitizing agent to eliminate or diminish reactivity of the patient to the PBC autoantigen.

In addition to use of the synthetic autoantigen in the detection of anti-mitochondrial antibody in a serum sample, the present invention extends to use of the synthetic peptide or polypeptide, or fragment, in the measurement of class-specific immunoglobulin titres using specific typing reagents. Applications also extend to the measurement of the affinity of either the whole autoantibody, or the affinity of individual classes or subclasses of the autoantibody. Affinity may be measured by a number of procedures, for example, by replicate ELISA assays performed using different washes of guanidine thiocyanate⁴². A further extension of the diagnostic

assay is the measurement of the degree of interference of autoantibodies with the enzymic function of the 70kd autoantigen (now shown to be lipoate acetyl transferase, see later). The source of the enzyme may be derived from expression of full length clones as native polypeptides or fusion polypeptides, or from expression of enzymatically active fragments or purified protein from mitochondria. The enzyme assay is a standard assay well known in the art, but modified to include a step of incubation with sample serum or cells. In yet a further extension of the use of the synthetic peptide or polypeptide, or fragment, there is included the measurement of reactivity of patient cells to the autoantigen. The synthetic peptide or polypeptide, or fragment, may be added, in solution or bound to a solid support, to patient cells derived from peripheral blood or from tissue biopsies either unfractionated, fractionated or as a continuous cell line. Reactivity to the autoantigen may then be measured by standard proliferation assays such as incorporation of tritiated thymidine, standard cytotoxic assays such as release of marker radioactivity from target cells, or other standard assays of cellular reactivity which are well known in the art.

In one particularly important aspect of this invention, there is provided a diagnostic test for detection of antimitochondrial antibody in a serum sample, which comprises the steps of:

- (i) contacting said serum sample with a synthetic peptide or polypeptide displaying portion of the 70kd mitochondrial autoantigen of PBC, or an antigenically active fragment thereof, said synthetic peptide or polypeptide being immobilized on a support, and
- (ii) detecting the presence of anti-mitochondrial

antibody in said serum bound to said synthetic peptide or polypeptide.

In this aspect, the invention also provides a diagnostic test kit for detection of anti-mitochondrial 5 antibody in a serum sample, which comprises:

- (i) a support having immobilised thereon a synthetic peptide or polypeptide displaying the antigenicity of all or a portion of the 70kd mitochondrial autoantigen of PBC, or an 10 antigenically active fragment thereof, and
- (ii) means for detecting the presence of anti-mitochondrial antibody in said serum bound to said synthetic peptide or polypeptide.

Preferably the detection of the presence of bound 15 AMA is by use of well known RIA or ELISA techniques.

As a result of the production of a recombinant fused polypeptide displaying the antigenicity of the 70kd mitochondrial autoantigen of PBC, this autoantigen has now been identified as lipoate acyltransferase. In addition, 20 the immunoglobulin isotypes of the anti-mitochondrial antibodies has been determined, and IgG3 has been found to be the predominant isotope in a group of PBC patients, with IgM next most prevalent. Comparison of serum immunoglobulin isotype levels of PBC patients with healthy 25 normal adults has shown that serum IgG3 and IgM were very elevated in PBC; IgG3 at 5.5 fold and IgM at 4.3 fold above normal.

In accordance with the present invention, expression of the cDNA insert encoding the mitochondrial 30 autoantigen, or fragments thereof, may be achieved in a number of different ways. The detailed description herein provides examples of expression as β -galactosidase fusion proteins in the vectors λ gt11 and pBTA224, using as host cells E.coli strains such as JM101, JPA101 and

7118. Successful expression of the autoantigen as a fusion protein may also be achieved using the well-known PVC vectors, or using the pGEX series which give expression of glutathione S-transferase fusion proteins, 5 again using E.coli as the host cells. Alternatively, the mitochondrial autoantigen may be expressed as a non-fused polypeptide, by using appropriate vector and host cell combinations. Other vector and host cell combinations which can be used in accordance with the present invention 10 including a number of well described yeast shuttle vectors growing in yeast cells, or eukaryotic vectors in continuous cell lines, or transgenic animals.

The identification, cloning and expression of the 70kd mitochondrial autoantigen of PBC in accordance with 15 the present invention, and its use in an ELISA, will now be described in detail, with reference to the accompanying drawings in which:

Figure 1 shows specificity of the fused 20 polypeptide. In lanes A and B, two different PBC sera at a dilution of 1/1000 were probed against lysates of pRMIT transformed JM101 cells. Both sera reacted with a polypeptide at 160kd. In contrast, in lanes C and D, the same sera were nonreactive when probed against lysates of 25 control cells containing an irrelevant insert that is also fused to β -galactosidase. The reactive bands in lanes C and D correspond to E.coli proteins. Duplicate blots probed with normal sera at 1/100 and 1/1000 failed to detect the fused polypeptide and are not shown. There is 30 some breakdown of the fusion protein with reactivity at 36kd.

Figure 2 shows identification of the pRMIT fused polypeptide. The reactivity of absorbed and unabsorbed PBC serum against human placental mitochondrial proteins

after PAGE was determined. In lane A, the probe was an unabsorbed PBC serum at a final dilution of 1/2000. In lane B, the probe was the same serum at a final dilution of 1/2000 after extensive absorption for 72hr against 5 cells transformed with non-recombinant pBTA224 and passage over a solid support to which had been bound a lysate of cells transformed with non-recombinant pBTA224. In lane C, the probe was the same serum at a final dilution of 1/2000 after absorption for 72hr against cells transformed 10 with non-recombinant pBTA224 and passage over a solid support to which had been bound a lysate of cells transformed with expressing pRMIT. The serum was also studied at 1/200 and 1/20,000 (Table II).

Figure 3 shows specificity of affinity-purified 15 antibody. In lane A, an unabsorbed PBC serum at 1,2000 was probed against placental mitochondria, reacting with both the 70 and the 45kd protein. In lane B, the column eluate was probed against the same mitochondrial preparation. Note the reactivity was only to the 70kd 20 protein, and the reduction in signal correspond to the expected recovery for such elution. Even on a very long autoradiographic exposure time of 1wk, there remained activity only to the 70kd protein (data not shown). In lane C, the eluate was probed against a sonicate of induced JM101 transformed with pRMIT. The intensity of 25 the 160kd fused polypeptide was due to the large quantity of fused polypeptide expressed. In lane D, the eluate was probed against a sonicate of induced JM101 transformed with an irrelevant plasmid that encodes an abundant fused 30 polypeptide.

Figure 4 shows immune response of BALB/c mice immunized with pRMIT induced fused polypeptide. Placental mitochondria were separated by PAGE on a 7.5% gel and blotted onto nitrocellulose, and the fractionated proteins

were probed with sera at a dilution of 1/1000 (lane A) or with serum from a patient with PBC at 1/1000: immunized mice produced antibody against the 70kd but not the 45kd protein.

5 Figure 5 shows immunofluorescence of HEp-2 cells. BALB/c mice were immunized with the purified fused polypeptide and sera incubated with HEp-2 cells. Note the typical mitochondrial pattern of reactivity.

10 Figure 6 shows nucleotide sequence of pRMIT and deduced amino acid sequence of the 70kd mitochondrial antigen of PBC.

15 Figure 7 shows comparison of sensitivity between the ELISA (+) and immunofluorescence (□) in detection of AMA in PBC. PBC sera were tested at every 10 fold dilution starting from 1:1000 in the ELISA whereas in the immunofluorescence against Hep-2 cells every 2 fold dilution starting from 1:10 was used. The positives on ELISA were defined as 2 S.D. O.D. units above the mean for normal sera.

20 Figure 8 shows the nucleotide sequence and deduced amino acid sequence of a 2.2kb cDNA insert that encodes the human equivalent of the sequence depicted in Figure 6, encompassing the human equivalent of the region of nucleotides 105-1065 in Figure 6. This human cDNA 25 clone was obtained by probing a human placental library using pRMIT as a hybridization probe according to known techniques. The sequences are highly homologous and have comparable reactivity with auto-mitochondrial antibodies; accordingly either antigen sequence could be used as the 30 basis of a diagnostic test to detect anti-mitochondrial antibodies or auto-reactive cells.

A. MATERIALS AND METHODS.Screening cDNA library.

A rat liver cDNA library in λ gt 11-Amp3 consisting of 15,000 recombinants, of average length of 5 1.4kb, was probed by using sera from patients with PBC. The sera used for screening were from each of three patients with classical PBC who were shown to have antibodies to mitochondria by immunoblot analysis of electrophoretically separated proteins of human placental 10 mitochondria². As some patients with PBC have high-titre antibodies to E.coli, the sera were extensively preabsorbed against E.coli infected with non-recombinant phage. The sera were used for probing at a final concentration of 1:1000^{11,12}. The λ -Amp3 library was 15 incubated with E.coli, strain ST9, for 15min at 37°C and then was plated for 2hr at 42°C in LB agar. Thereafter, nitrocellulose filters that had been previously soaked in 10ml isopropyl-thiogalactosidase (IPTG) and allowed to air dry were overlayed on each plate. The plates were then 20 incubated overnight at 37°C. The nitrocellulose was removed after alignment and was washed for 1hr in PBS with 5% milk powder, pH 7.4. The filters were then incubated for 45min with previously absorbed sera of patients with PBC, washed three times for 30min, and incubated with 25 ¹²⁵I-protein A (300,000 cpm/ml) for 45min. Finally, the filters were washed three times, were allowed to air dry, and were placed on XRP-1 film with an intensifying screen for an overnight (12hr) exposure. All washings and dilutions of sera and ¹²⁵I-protein A were done with milk 30 powder. Putative positive clones were picked and rescreened for plaque purification^{12,13}.

Subcloning.

Three clones gave positive signals, a frequency of approximately one in 50,000 clones. These positive 35 clones were plaque purified. Each of these clones yielded an identical sized insert of approximately 1.4kd. The

inserts were subcloned in the plasmid vector pBTA224, which is a high copy plasmid expression vector with a site for insertion of foreign DNA identical to that of λ-Amp3. Therefore, 50% of the subclones should also give a positive signal on an immunoassay as the insert is in the same reading frame as λ-Amp3. Clones expressing an unrelated rat liver cDNA (the F alloantigen) were used as controls. Arrays of pBTA224 colonies were prepared to identify immunoreactive clones. Colonies were incubated for 16hr at 37°C, then were induced with 10mM IPTG for 4hr. The colonies were lysed and prepared for antibody probing as described¹¹. Filters were probed with either a 1/1000 dilution of absorbed PBC sera or a 1/100 dilution of normal serum. One positive clone, designated pRMIT, that expressed a fused polypeptide of 160kd was selected for further study.

Immunoblotting of mitochondrial proteins.

Mitochondria from human placenta were prepared as described^{2,14}. Polyacrylamide gel electrophoresis (PAGE) was performed on 1mm-thick slab gels in 0.1% SDS, using a 3.8% stacking gel and a 10% resolving gel. Before PAGE, the purified mitochondria were suspended at a concentration of 4mg protein/ml and were incubated for 30min with 10,000 U of bovine pancreatic DNase 1 at 37°C, and then were held with an equal volume of 3% aqueous octyl glucoside for 15min at 4°C. The final preparations were diluted with Tris-HCl, pH6.8, containing 4% SDS, 20% glycerol, and 5% 2-mercaptoethanol (sample buffer) and were boiled for 5min. Approximately 10μg protein were loaded in each gel lane².

Specificity of pRMIT fused polypeptide.

To demonstrate that pRMIT expressed an antigen specifically reactive with sera from patients with PBC, lysates of the expressing clone were probed with sera from

healthy persons or from patients suffering from different autoimmune diseases. Briefly, a 100ml overnight culture of JM101 cells transformed with pRMIT was diluted 1/10 in L-broth containing 10mM IPTG. Four hours later the cultures were spun at 5000xG for 10min and were snap frozen after addition of 20ml of phosphate-buffered saline. PAGE was performed on 1mm-thick slab gels with 0.1% SDS, using a 3.8% stacking gel and a 7.5% resolving gel. Samples were diluted 1/100 in the above sample buffer and were boiled for 5min. Each lane contained approximately 5 to 10 μ g of protein. The samples were probed with PBC sera diluted at 1/1000, and the reactivity was determined as above, using 125 I-protein A and exposure for 18hr. These same sera also were used to probe immunoblots of lysates of non-recombinant control clones or clones expressing a fused polypeptide coded by an irrelevant DNA insert. The sera used were from patients with PBC, systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, chronic active hepatitis and from healthy normal volunteers. All control sera were studied at a dilution of 1/100.

Identification of fused polypeptide.

The fused polypeptide expressed by pRMIT was characterised to determine whether it was a mitochondrial antigen recognised by PBC sera. The clone pRMIT was grown in liquid culture overnight. It was thence put into log phase and induced to give maximal expression of the fused polypeptide with 10mM IPTG for 4hr. Bacterial lysates were prepared as above and coupled to cyanogen bromide-Sepharose¹⁵. This solid support was then used as an affinity reagent to bind antibodies selectively from seven different PBC sera. First, sera from seven patients with PBC were absorbed extensively with sonicates of E.coli transformed with non-recombinant pBTA224. Thence,

the sera at dilutions of 1/200, 1/2000, and 1/20,000 were passed through the lysate of pRMIT-transformed bacteria bound to a solid support. The nonabsorbed antibodies were collected, compared with unmanipulated sera at the same final dilution, and used to probe placental mitochondria, prepared as above.

Preparation of affinity-purified antibody.

Affinity-purified antibody was prepared by first extensively preabsorbing five different reactive sera with sonicates of JM101, which had been transformed with non-recombinant pBTA224, and then passing this absorbed serum over a column of JM101 transformed with non-recombinant pBTA224¹⁵. Each serum was passed over a column of induced JM101 cells transformed with pRMIT, and the column was washed for 24hr with 100-fold the bed volume of the column. Thence, lycine HCl was used to elute the bound antibodies¹⁵. The antibodies that had bound to the pRMIT absorbent were probed against fractionated placental mitochondria, a lysate of expressing pRMIT, and a lysate of a control recombinant clone. They were also reacted by immunofluorescence with either HEp-2 cells or kidney tissue sections.

Isolation of mitochondrial antigen expressed as fused polypeptide.

Isolation of the fused polypeptide was performed by using gel filtration in the presence of SDS to fractionate the insoluble pellet and to obtain material suitable for immunization. A clone of pRMIT was incubated overnight at 37°C in L-broth containing 10µg/ml ampicillin. Eighteen hours later it was diluted for log phase growth and was induced with 10mM IPTG for 4hr. The *E.coli* preparation was then harvested at 5000xG for 10min, and the pellets were resuspended in 40ml of 10mM Tris-HCl, pH8.0, containing 2mM EDTA. Lysozyme was then added to a

final concentration of 0.25mg/ml, and the mixture was rotated for 30min at room temperature. The solution was made up to 0.2% of Triton X-100 with continuous mixing for an additional 10min at room temperature. An equal volume of 10mM Tris-HCl with 2mM EDTA, 50mM NaCl, and 10mM MgCO₂ was added with a final concentration of 2mg/ml DNase. This was allowed to rotate for 15min at room temperature and then was spun at 1500xG for 5min. The pellet was discarded and the supernatant was spun for 30min at 10,000xG. This final pellet was then fractionated on a Sephadryl S-300 column in tandem with a Sephadryl S-400 column, after dispersion of the pellet in 0.1 M phosphate buffer, pH 6.0, with 2% SDS and 10mM dithiothreitol (DTT). The fractions were eluted at 50ml/hr, and 6-min fractions were collected for assay by analytical SDS-PAGE and immunoblotting. SDS was finally removed on a hydroxyapatite column after dilution with 0.5M phosphate buffer, pH6.8, and 1mM DTT. The purity of fractions was confirmed by SDS-PAGE and immunoblotting as above.

Immunization of mice.

Groups of six BALB/c female mice were immunized with 10 μ g of purified fused polypeptide in complete Freund's adjuvant (CFA). Three weeks later they were boosted with the same dose in CFA. Six weeks after the initial immunization, mice were bled and the sera were isolated. These sera were assayed at a dilution of 1/1000 and were probed against PAGE-separated placental mitochondria as above except that affinity-purified ¹²⁵I-goat anti-mouse Ig was used. The sera were also studied at 1/100 by immunofluorescence, using sections of HEp-2 cells and kidney tissue sections as described^{1,2,5}.

Nucleotide and amino acid sequence.

The cDNA insert of pRMIT was subcloned into M13.

and the nucleotide sequence as determined^{16,17}. The correct frame and orientation of the insert was determined by double-stranded sequencing of an expressing clone¹⁷. The sequence was determined in both orientations, and use
5 was made of synthetic oligonucleotides to prime reactions¹⁸.

ELISA

Briefly, the purified recombinant fused polypeptide at 2µg/ml, diluted in carbonate buffer, was
10 absorbed to Immulon 1 microtitre plates (Dynatech Laboratories, Alexandria, VA) overnight at 4°C. After blocking the non-specific sites with foetal calf serum (FCS) buffer (5% FCS, 1% BSA, 0.3% gelatin in PBS), PBC sera diluted in FCS buffer, were incubated for one hour.
15 The plates were washed three times with PBS/0.1% tween and then incubated with each of the following mouse monoclonal antibodies specific against human heavy chain isotypes: SG-11 for IgG1, GOM-1 for IgG2, SJ-33 for IgG3, SK-44 for IgG4, MB-11 for IgM and GA-1 for IgA (Miles Scientific, Naperville, IL). The binding of mouse MoAbs were detected
20 with peroxidase conjugated goat anti-mouse IgG (Tago, Burlingame, CA) for all except SJ-33 which was detected with peroxidase conjugated goat anti-mouse IgM (Tago, Burlingame, CA). ABTS was used as the colour substrate
25 for the peroxidase. For detection of all isotypes of AMA, HRP-G Hulg was used in the place of isotype specific monoclonals.

Human myeloma proteins were used to obtain the optimal dilutions of the isotype specific MoAbs.
30 Predetermined dilutions of myeloma proteins were coated onto microtitre plates and ELISA performed as before with serial dilutions of isotype specific MoAbs followed by the peroxidase conjugated reagents. The dilutions of isotype specific MoAbs which gave similar O.D. units at

approximately equal serum isotype concentrations were used in the ELISA.

To obtain the optimal serum dilutions for screening, previously screened (by immunofluorescence)

- 5 AMA-positive PBC, progressive sclerosing cholangitis and normal sera were titrated by the ELISA. It was found that a serum dilution of 1:1000 yielded the highest signal to noise ratio, and this dilution was used to obtain all results. The cut-off point for negatives were determined
10 as 2 standard deviation above the mean O.D. of normal sera.

B. RESULTS

Arrays of pRMIT in BTA224.

- Subclones of pRMIT in JM101 were very
15 immunoreactive when probed with sera from patients with PBC, whereas control clones were nonreactive. In contrast, sera from normal volunteers reacted with neither pRMIT in JM101 nor control clones. Positive colonies from arrays were used in all subsequent studies.

20 Specificity of pRMIT fused polypeptide.

- Sera at dilutions of 1/1000 from 25 of 25 patients with PBC reacted with a 160kd fused polypeptide made in pRMIT (Table I and Fig.1). This band also reacted with a rabbit antiserum to β -galactosidase (data not shown). A number of bands corresponding to components of lower m.w. also were recognised, including one at approximately 36kd, which was apparently a breakdown product of the 160kd molecule. These lower m.w. materials were only associated with pRMIT and were immunoreactive
25 with PBC sera. The titre of reactivity for these 25 sera ranged from 1:1000 to 1:1,000,000. With the use of the same 25 sera, the fused polypeptide was not detected in lysates of bacteria produced by non-recombinant pBTA224 or bacteria transformed with an irrelevant insert and induced
30

to express an abundant fused polypeptide. None of the sera from patients with systemic lupus erythematosus, rheumatoid arthritis, or chronic active hepatitis reacted with the fused protein at dilutions of 1/100, even with 5 autoradiographic exposures of up to 4 days.

TABLE 1. Reactivity of human sera with the pRMIT fused polypeptide.

	Group ^a	No. positive ^b /Total
5	PBC	25/25
	Normal persons	0/25
	Systemic lupus erythematosus	0/21
	Rheumatoid arthritis	0/18
10	Chronic active hepatitis	0/32

a PBC sera were studied at 1/1000 sera dilution; other groups were studied at 1/100 sera dilution.

15 b A positive blot was one in which reactivity to a band of 160kd was readily visible after an autoradiographic exposure level of 12hr. See Figure 1.

Identification of fused polypeptide.

20 After absorption with the lysate of pRMIT, sera from all seven patients with PBC were shown to be depleted of antibodies reactive with the 70kd antigen (Table II). In contrast, such absorption did not change the reactivity to the 45kd or 39kd antigen. No such depletion was seen when 25 PBC sera were absorbed against a lysate of a control clone bound to a solid support. The finding that the reaction of PBC sera with the pRMIT fused polypeptide appeared to remove detectable anti-70kd reactivity indicates that the cDNA encodes all determinants recognised by the 30 autoantibodies to the 70kd antigen (Table II; Fig. 2).

Affinity-purified antibodies.

The eluted antibodies of five different PBC sera reacted with the 70kd polypeptide of fractionated placental mitochondria and with the 160kd fused

polypeptide in pRMIT (Fig.3), further indicating that pRMIT encodes the 70kd antigen. The eluted antibodies did not react with a lysate of bacterial proteins from a clone expressing a control liver cDNA. The eluted antibodies 5 also gave a characteristic pattern of anti-mitochondrial staining by immunofluorescence with either HEp-2 cells or kidney tissue sections.

Immune response of mice.

BALB/c mice, after injection of the pRMIT fused 10 polypeptide, gave an antibody response to the 70kd placental mitochondrial protein. Control nonimmunized mouse sera was nonreactive (Fig.4). In addition, these sera produced a typical pattern of anti-mitochondrial immunofluorescence on both HEp-2 cells and kidney tissue 15 sections (Fig.5).

Nucleotide and amino acid sequence.

The insert is 1370 base pairs long and consists entirely of coding region (Fig.6). The 456 amino acids would code for a polypeptide of approximately 48kd, 20 consistent with the observed size of the fused polypeptide produced by the clone; it is thus not a full-length sequence of the antigen. The sequence contains 11% proline, and the proline is frequently found preceded by short stretches of hydrophobic amino acids such as alanine 25 and valine, e.g., from nucleotides 54 to 102. Comparison of the sequence of the 70kd mitochondrial autoantigen with known protein and DNA sequences did not reveal any closely homologous sequences. The sequence is not present in mitochondrial DNA (data not shown), and the 70kd protein 30 is therefore coded for by nuclear genes.

The sensitivity of ELISA was compared with immunofluorescence for 37 patients with PBC (Figure 7). ELISA was found to be approximately 250 fold more sensitive; the average titre detected by ELISA was 35 $10^{5.4}$ whereas by immunofluorescence it was only 10^3 .

TABLE II. Absorption of PBC sera with the pRMIT fused polypeptide

Patient	Preabsorption Titre ^a			Postabsorption Titre ^a		
	70kd	45kd	39kd	70kd	45kd	39kd
1	1:2,000	1:2,000	0	0	1:2,000	0
2	>1:20,000	1:20,000	0	1:200	1:2,000	0
3	>1:20,000	>1:20,000	1:2,000	1:200	>1:20,000	1:2,000
4	1:2,000	1:200	0	0	1:200	0
5	>1:20,000	>1:20,000	1:2,000	1:200	>1:20,000	1:2,000
6	1:2,000	0	0	0	0	0
7	>1:20,000	1:2,000	0	0	1:2,000	0

a Reactivity on immunoblots using placental mitochondria as described; absorption with control lysates does not influence the titre.

REFERENCES

1. Berg, P.A., Klein, R. and Lindenborn-Fotinos,
J.J. Hepatology 2:123-131, 1986.
2. Frazer, I.H., Mackay, I.R., Jordan, Wittingham,S.
and Marzuki, S. J.Immunol. 135:1739-1745, 1985.
3. Kenna, J.G., Neuberger, J., Davies, E.,
Eddleston, A.L.W.F., and Williams, R.
J.Immunol. Methods 73:401-413, 1984.
4. Kaplan, M.M., Gandolfo,J.V., Quaroni, E.G.
Hepatology 4:727-730, 1984.
5. Walker, J.G., Doniach, D., Roitt, I. and
Sherlock, S. Lancet 1:827-831, 1965.
6. Lindenborn, Fotinos, J., Baum, H. and Berg, P.A.
Hepatology 5:763-769, 1985.
7. Mendel-Hartvig, I., Nelson, B.D., Loof, L., and
Totterman, T.J. Clin. Exp. Immunol. 62:371-379,
1985.
8. Baum, H. and Palmer, C. Mol.Aspects Med. 8:201,
1985.
9. Miyachi, K., Watanabe, S., Yamashiki, Hiwatashi,
T. and Ichida, F. Am.J.Gastro. 79:704-709, 1984.
10. Uzoegwu, P.N., Baum, H. and Williamson, J. Cell
Biol. Intl. Reports 8:987-992, 1984.
11. Kemp, D.J., Coppel, R.L., Cowman, A.F., Saint,
R.B., Brown, G.V. and Anders, R.F.
Proc.Natl.Acad.Sci.USA 80:3787-3791, 1983.
12. Young, A.A. and Davis, R.W. Science 222:778, 1983.
13. Stahl, H.D., Coppel, R.L., Brown, G.V., Saint,
R., Lingelbach, K., Cowman, A.F., Anders, R.F.and
Kemp, D.J. Proc.Natl.Acad.Sci. USA 81:2456, 1984.
14. Hare, J.F., Ching, E. and Attardi, G.
Biochemistry 19:2023-2027, 1980.

15. Crewther, P.E., et.al. J.Immunol.Meth. 86:257-264, 1986.
16. Messing, J. and Vieira, J. Gene 19:269-276, 1982.
17. Sanger, F. Science 214:1205, 1981.
18. Vieira, J. and Messing, J. Gene 19:259, 1982.
19. Smith, N.D. and Boyer, J.L. Hepatology 6:739, 1986.
20. Hurt, E.C. and vanLoon, A.P.G.M. Trends Biochem.Sci. 2:204, 1986.
21. Anderson, S., Bankier, A.T., Barrell, B.G., deBruin, M.H.L., Coulson, A.R., Drouin, J., Eperon, I.C., Nierlich, D.P., Roe, B.A., Sanger, F., Schreier, P.H., Smith, A.J.H., Staden, R. and Young, I.G.. Nature 290:457, 1981.
22. Andereson, S., deBruin, M.H., Coulson, A.A., Eperon, I.C., Sanger, F. and Young, I.G. J.Mol.Biol. 156:683, 1982.
23. Berg, P.A. and Baum, H. Sem.Immunopath. 3:355-373, 1980.
24. Klein, R., Lindenborn, J. and Berg, P.A. J.Immunol.Methods 64:227-238, 1983.
25. Miyachi, K., Gupta, R.C., Dickson, E.R. and Tan, E.M. Clin.Exp.Immunol. 39:599-606, 1980.
26. Munoz, L.E., Thomas, H.C., Scheurer, P.J., Doniach, D. and Sherlock, S. Gut. 136-140, 1981.
27. Taal, B.G., Schalm, S.W., Ten Kate, F.W.J., Hermans, J., Geertzen, R.G. and Feltkamp, B.E.W. Hepato-Gastro. 30:178-182, 1984.
28. Eriksson, S. and Lindgren, S. Scand.J.Gastro. 19:971-976, 1984.
29. Berg, P.A., Wiedmann, K.H., Sayers, T., Kloppel, G. and Lindner, H. Lancet 1:1329, 1980.

30. Weber, P., Brenner, J., Stechemesser, E., Klein, R., Weckenmann, U., kloppel, G., Kirchhof, M., Fintelmann, V. and Berg, P.A. Hepatology 6:553, 1986.
31. Modena, V., Marengo, C., Amoroso, A., Rosina, F., Costantini, P., Bellando, P., Coppo, R. and Rizzetto, M. Clin.Exp.Rheumatol. 4:129, 1986.
32. Udeenfelt, F. and Danielsson, A. Ann.Clin.Res. 18:148, 1986.
33. Schultheiss, H.-P., Berg, P.A. and Klingenberg, M. Clin.Exp.Immunol. 58:596, 1984.
34. James, S.P., Hoofnagle, J.H., Strober, W. and Jones, E.A. Ann.Int.Med. 99:500, 1983.
35. Namihisa, T., Kuroda, H. and Imanari, H. Jpn.Soc.Gastroenterol. 18:445, 1983.
36. Van den Oord, J.J., Fevery, J., De Groote, J. and Desmet, V.J. Liver 4:264, 1984.
37. Shimizu, M., Yuh, K., Aoyama, S., Ichihara, I., Watanabe, H., Shilo, H. and Okumura, M. Liver 6:1, 1986.
38. Avigan, M.I., Adamson, G., Hoofnagle, J.H. and Jones, E.A. Hepatology 6:999, 1986.
39. Fennell, R.H. Pathol.Annu. 16(Pt.2):289, 1981.
40. Neuberger, J., Portmann, B., Macdougall, B.R.D., Calne, R.Y. and Williams, R. N Engl.J.Med. 306:1, 1982.
41. Handley, H.H., Glassy, M.C., Cleveland, P.H. and Roystan, I. J.Immunol.Meth. 54:291-298, 1982.
42. MacDonald, R.A., Hosking, C.S. and Jones, C.L. J.Immunol.Meth. In press, 1987.

CLAIMS:

1. A DNA molecule comprising a nucleotide sequence substantially corresponding to all or a portion of the base sequence coding for the 70kd mitochondrial autoantigen of primary biliary cirrhosis (PBC), or an antigenically active fragment thereof.
2. A DNA molecule according to claim 1, characterised by at least a portion thereof comprising a base sequence substantially as shown in Figure 6 or Figure 8, or a fragment thereof.
3. A DNA molecule according to claim 2, characterised by at least a portion thereof comprising a base sequence corresponding substantially to nucleotides 76-679 as shown in Figure 6.
4. A DNA molecule according to claim 2, characterised by at least a portion thereof comprising a base sequence coding for the amino acid sequence:
A E I E T D K A T I G F E V Q E E G Y L.
5. A recombinant DNA molecule comprising a nucleotide sequence as claimed in any of claims 1 to 4, operatively linked to an expression control sequence.
6. An expression vector containing a nucleotide sequence as claimed in any of claims 1 to 4, operatively linked to an expression control sequence.
7. A transformed host cell containing a nucleotide sequence as claimed in any of claims 1 to 4, operatively linked to an expression control sequence.

8. A synthetic peptide or polypeptide displaying the antigenicity of all or a portion of the 70kd mitochondrial autoantigen of primary biliary cirrhosis, or an antigenically active fragment thereof.

9. A synthetic peptide or polypeptide according to claim 8, characterised by at least a portion thereof comprising an amino acid sequence substantially as shown in Figure 6 or Figure 8, or an antigenically active fragment thereof.

10. A synthetic peptide or polypeptide according to claim 9, characterised by at least a portion thereof, comprising an amino acid sequence substantially as coded for by nucleotides 76-679 as shown in Figure 6.

11. A synthetic peptide or polypeptide according to claim 9, characterised by at least a portion thereof comprising the amino acid sequence:

A E I E T D K A T I G F E V Q E E G Y L.

12. A process for preparing a synthetic peptide or polypeptide as claimed in claim 8, which comprises cultivating a transformed host cell as claimed in claim 5 under suitable conditions, and isolating and purifying the expressed peptide or polypeptide.

13. Use of a synthetic peptide or polypeptide as claimed in any of claims 8 to 11, as an antigen in a diagnostic test.

14. Use of a synthetic peptide or polypeptide as claimed in any of claims 8 to 11, in the treatment of patients.

15. A diagnostic test for detection of anti-mitochondrial antibody in a serum sample, which comprises the steps of:

- (i) contacting said serum sample with a synthetic peptide or polypeptide displaying the antigenicity of all or a portion of the 70kd mitochondrial autoantigen of PBC, or an antigenically active fragment thereof, said synthetic peptide or polypeptide being immobilized on a support, and
- (ii) detecting the presence of anti-mitochondrial antibody in said serum bound to said synthetic peptide or polypeptide.

16. A diagnostic test kit for detection of anti-mitochondrial antibody in a serum sample, which comprises:

- (i) a support having immobilised thereon a synthetic peptide or polypeptide displaying the antigenicity of all or a portion of the 70kd mitochondrial autoantigen of PBC, or an antigenically active fragment thereof, and
- (ii) means for detecting the presence of anti-mitochondrial antibody in said serum bound to said synthetic peptide or polypeptide.

1/11




FIG. 1.

2/11




FIG. 2.

FIG. 3.

SUBSTITUTE SHEET

3/11




FIG. 4.

SUBSTITUTE SHEET

WO 88/04689

PCT/AU87/00427

4/11




FIG. 5.

SUBSTITUTE SHEET

5/11

Gly Pro Glu Ala Phe Lys Asn Tyr Thr Leu Asp Ser Ala Thr				
GGG CCT GAGG CTT TAAA ATT ATAC ATG GATT CAG CAACA				
10	20	30	40	
Pro Ala Ala Pro Ser Ala Ser Ala Pro Gly Ser Ser Tyr Pro				
CCAG CTG CAC CCT CTG CAAG TGCT CCAG GTAG CTCC ATCCC				
100	110	120	130	
Gly Thr Val Gln Arg Trp Glu Lys Lys Val Gly Glu Lys Leu				
GGC ACC CGT CCAG AGGT GGG AAA AGA AAAGT GGG AGAGA AGCT G				
190	200	210	220	
Gly Phe Glu Val Gln Glu Glu Gly Tyr Leu Ala Lys Ile Leu				
GGCT TTGA AGT ACA AGA AAG GTT ATCT GGCA AAA ATCC TG				
280	290	300	310	
Ile Val Glu Lys Gln Glu Asp Ile Ala Ala Phe Ala Asp Tyr				
ATAG TAG AAA ACAG GAAG ATAT AGC AGC ATT GCAG ACT AC				
370	380	390	400	
Pro Pro Pro Val Ala Ala Val Pro Pro Ile Pro Gln Pro Leu				
CCAC CCCCCAGT GG CAG CTG TT CCT CCC ATC CCCC AGC CCT TA				
460	470	480	490	
Val Ser Pro Leu Ala Lys Lys Leu Ala Ala Glu Lys Gly Ile				
GTT AGC CCT CTT GCAA AGAA ATT GGC AGC AGA AAAGGG ATT				
550	560	570	580	
Lys Asp Ile Asp Ser Phe Val Pro Thr Lys Ala Ala Pro Ala				
AAGG AC ATT GACT CTTT GTGC CT ACT AAGG CTG CT C TGCC				
640	650	660	670	

FIG. 6a.

6/11

Ala	Ala	Thr	Gln	Ala	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Pro	Ala	Ala	Ala
GCTGCCACACAGGCAGCCCCAGCCCCAGCTGAGCTCCAGCTGCTGCC															
50	60	70	80												90
Val	His	Met	Gln	Ile	Val	Leu	Pro	Ala	Leu	Ser	Pro	Thr	Met	Thr	Met
GTTCACATGCAGATT															
140	150	160	170												180
Ser	Glu	Gly	Asp	Leu	Leu	Ala	Glu	Ile	Glu	Thr	Asp	Lys	Ala	Thr	Ile
AGTGAAGGAGACTTGCTGGCAGAGATAAGAGACC															
230	240	250	260												270
Val	Pro	Glu	Gly	Thr	Arg	Asp	Val	Pro	Leu	Gly	Thr	Pro	Leu	Cys	Ile
GTCCCTGAAGGCACAAGGGATGTTCTCTGGGAAACCCGCTATGTATC															
320	330	340	350												360
Arg	Pro	Thr	Glu	Val	Thr	Ser	Leu	Lys	Pro	Gln	Ala	Pro	Pro	Pro	Val
AGGCCAACAGAAGTGACCAAGCTTAAAGCCACAGGCACCAACCACCTGTC															
410	420	430	440												450
Ala	Pro	Thr	Pro	Ser	Ala	Ala	Pro	Ala	Gly	Pro	Lys	Gly	Arg	Val	Phe
GCACCTACCCCCCTCAGCC															
500	510	520	530												540
Asp	Leu	Thr	Gln	Val	Lys	Gly	Thr	Gly	Pro	Glu	Gly	Arg	Ile	Ile	Lys
GACCTCACCCAAAGTTAAAGGGACGGGACCAGAAGGCAGAACATCATCAAG															
590	600	610	620												630
Ala	Ala	Ala	Ala	Ala	Pro	Pro	Gly	Pro	Arg	Val	Ala	Pro	Thr	Pro	Ala
GCTGCAGCAGCTGCTCCCCCGGGTCCAAGAGTGGCACCAACTCCTGCA															
680	690	700	710												720

FIG. 6b.

7/11

GlyValPheIleAspIleProIleSerAsnIleArgArgVal
GGTGTCTTCATAGACATCCCCTACAGCAACATTGTCGAGTG
730 740 750 760

LeuSerValAspValAsnMetGlyGluValLeuLeuValArg
CTTTCTGTTGATGTAATATGGGAGAGGTGCTGTTGGTGCAGG
820 830 840 850

AspPheIleIleLysAlaSerAlaLeuAlaCysLeuLysVal
GACTTCATCATAAAAGCTTCAGCTTGGCCTGCCTGAAAGTT
910 920 930 940

ValValAspValSerValAlaValSerThrProAlaGlyLeu
GTGGTTGATGTCAGCGTTGCTGTCAGTACCCCTGCAGGACTT
1000 1010 1020 1030

AlaSerAspValValSerLeuAlaSerLysAlaArgGluGly
GCTAGTGTGTTGTTCTTAGCCTCAAAGCAAGAGAGGGT
1090 1100 1110 1120

LeuGlyMetPheGlyIleLysAsnPheSerAlaIleIleAsn
TTAGGGATGTTGGAATTAAAGAATTCTCTGCGATTATTAAC
1180 1190 1200 1210

IleProAlaAspAsnGluLysGlyPheAspValAlaSerVal
ATCCCCTGCAGATAATGAGAAAGGCTTGACGTGGCTAGTGTG
1270 1280 1290 1300

LeuGluProSerGlyLeuLeu
TTGGGAGCCCAGTGGCTTGCT
1360 1370

FIG. 6c.

8/11

IleAlaGlnArgLeuMetGlnSerLysGlnThrIleProHisTyrTyr
ATTGCGCAGAGGCTCATGCAGTCGAAGCAGACTATACCTCATTATTAC
770 780 790 800 810
LysGluLeuAsnLysMetLeuGluGlyLysGlyLysIleSerValAsn
AAGGAACCTTAATAAGATGCTTGAAGGTAAAGGAAAAATCTCCGTCAAT
860 870 880 890 900
ProGluAlaAsnSerSerTrpMetAspThrValIleArgGlnAsnHis
CCTGAAGCAAACATCTGGATGGACACAGTTACGACAAAATCAT
950 960 970 980 990
IleThrProIleValPheAsnAlaHisIleLysGlyLeuGluThrIle
ATCACCCCTATTGTGTTAACGCACACATAAAAGGACTGGAAACCATT
1040 1050 1060 1070 1080
LysLeuGlnProHisGluPheGlnGlyGlyThrPheThrIleSerAsn
AAACTTCAGCCTCACGAGTTCCAGGGTGGGACATTACAATCTCCAAC
1130 1140 1150 1160 1170
ProProGlnAlaCysIleLeuAlaIleGlyAlaSerGluAspLysLeu
CCACCTCAGGCATGTATTTGGCAATTGGTGCTTCCGAGGATAAACTG
1220 1230 1240 1250 1260
MetSerValThrHisSerAlaValIleIleGluLeuTrpMetGluGln
ATGTCTGTCACACACTCAGCTGTGATCATCGAGTTGGGATGGAGCAG
1310 1320 1330 1340 1350

Fig. 6d.

9/11




FIG. 7.

10/11

Pro Gly Ser Ser Tyr Pro Pro His Met Glu Val Leu Leu Pro Ala
 CCTGGTAGCTCATATCCCCCTCACATGCAGGTACTTCTTCCTGCC
 10 20 30 40
 Lys Val Gly Glu Lys Leu Ser Glu Gly Asp Leu Leu Ala Glu Ile
 AAAGTGGGTGAGAAGCTAACGTGAAGGAGACTTAC TGGCAGAGATA
 100 110 120 130
 Tyr Leu Ala Lys Ile Leu Val Pro Glu Gly Thr Arg Asp Val Pro
 TATCTGGCAAAAATCCCTGGTCCCTGAAGGCACAAGAGATGTCCCT
 190 200 210 220
 Ser Ala Phe Ala Asp Tyr Arg Pro Thr Glu Val Thr Asp Leu Lys
 TCAGCATTGCTGACTATAGGCCAACCGAAGTAACAGATTTAAAA
 280 290 300 310
 Pro Thr Pro Gln Pro Leu Ala Pro Thr Pro Ser Ala Pro Cys Pro
 CCAACTCCCCAGCCTTAGCTCCTACACCTCAGCACCCCTGCCCA
 370 380 390 400
 Ala Lys Lys Leu Ala Val Glu Lys Gly Ile Asp Leu Thr Glu Val
 GCAAAGAAGTTGGCAGTAGAGAAAGGGATTGATCTTACACAAGTA
 460 470 480 490
 Ser Phe Val Pro Ser Lys Val Ala Pro Ala Pro Ala Ala Val Val
 TCTTTGTGCCCTAGTAAAGTTGCTCCTGCTCCGGCAGCTGTTGTG
 550 560 570 580
 Thr Asp Ile Pro Ile Ser Asn Ile Arg Arg Val Ile Ala Glu Arg
 ACAGATATCCAATCAGAACATTCTGGTGGGTTATTGCACAGCGA
 640 650 660 670
 Asp Val Asn Met Gly Glu Val Leu Leu Val Arg Lys Glu Leu Asn
 GATGTAATATGGGAGAAGTTTGTTGGTACGGAAAGAACTTAAT
 730 740 750 760
 Ile Lys Ala Ser Ala Leu Ala Cys Leu Lys Val Pro Glu Ala Asn
 ATAAAAGCTCAGCTTGGCATGTTAAAAGTTCCCGAAGCAAAT
 820 830 840 850
 Val Ser Val Ala Val Ser Thr Pro Ala Gly Leu Ile Thr Pro Ile
 GTCACTGTTGCGGTCAGTACTCCTGCAGGACTCATCACACCTATT
 910 920 930 940

FIG. 8a.

///

Leu	Ser	Pro	Thr	Met	Thr	Met	Gly	Thr	Val	Gln	Arg	Trp	Glu	Lys
CTCTCTCCCACCATGACCATGGGCACAGTTAGAGATGGGAAAAAA														
50	60	70	80	90										
Glu	Thr	Asp	Lys	Ala	Thr	Ile	Gly	Phe	Glu	Val	Gln	Glu	Gly	
GAAACTGACAAAGCCACTATAGGTTTGAAAGTACAGGAAGAAGGT														
140	150	160	170	180										
Leu	Gly	Thr	Pro	Leu	Cys	Ile	Ile	Val	Glu	Lys	Glu	Ala	Asp	Ile
CTAGGAACCCCACCTCTGTATCATTGTAGAAAAAGAGGCAGATATA														
230	240	250	260	270										
Pro	Gln	Val	Pro	Pro	Pro	Thr	Pro	Pro	Pro	Val	Ala	Ala	Val	Pro
CCACAAAGTGCCACCACTACCTACCCCCACCCCCCGGTGGCCGCTGTTCC														
320	330	340	350	360										
Ala	Thr	Pro	Ala	Gly	Pro	Lys	Gly	Arg	Val	Phe	Val	Ser	Pro	Leu
GCTACTCCTGCTGGACCAAAGGGAAAGGGTGTGTTAGCCTCTT														
410	420	430	440	450										
Lys	Gly	Thr	Gly	Pro	Asp	Gly	Arg	Ile	Thr	Lys	Lys	Asp	Ile	Asp
AAAGGGACAGGACCAGATGGTAGAACATACCAAGAAGGATATCGAC														
500	510	520	530	540										
Pro	Pro	Thr	Gly	Pro	Gly	Met	Ala	Pro	Val	Pro	Thr	Gly	Val	Phe
CCTCCCCACAGGTCCTGGAAATGGCACCAAGTTCTACAGGTGTCTTC														
590	600	610	620	630										
Leu	Met	Gln	Ser	Lys	Gln	Thr	Ile	Pro	His	Tyr	Tyr	Leu	Ser	Ile
TTAATGCAATCAAAGCAAACCATACCTCATTATTACCTTTCTATC														
680	690	700	710	720										
Lys	Ile	Leu	Glu	Gly	Arg	Ser	Lys	Ile	Ser	Val	Asn	Asp	Phe	Ile
AAGATATTAGAAGGGAGAAGCAAAATTCTGTCAATGACTTCATC														
770	780	790	800	810										
Ser	Ser	Trp	Met	Asp	Thr	Val	Ile	Arg	Gln	Asn	His	Val	Val	Asp
TCTTCTTGGATGGACACAGTTATAAGACAAAATCATGTTGTTGAT														
860	870	880	890	900										
Val	Phe	Asn	Ala	His	Ile	Lys								
GTGTTTAATGCACATATAAAA														
950	960													

Fig. 8b.

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No PCT/AU 87/00427

I. CLASSIFICATION OF SUBJECT MATTER (1 several classification symbols apply, indicate all)

According to International Patent Classification (IPC) or to both National Classification and IPC
 Int. Cl. 4 C12N 15/00, C07G 17/00, C07H 21/04, C07K 15/12, 13/00, 7/08,
 C12N 9/10, 1/20, G01N 33/543

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System	Classification Symbols
IPC	WPI, WPIL, USPA : Keyword: Biliary Cirrhosis (Derwent Databases)

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

AU: IPC as above; Chemical Abstracts : Keyword: Biliary Cirrhosis;
GenBank, NBRF, EMBL, Kyoto Databases

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *¹ Citation of Document, *² with indication, where appropriate, of the relevant passages *³ | Relevant to Claim No. *⁴

- P,X Chemical Abstracts, Volume 107, no. 3, issued 20 July 1987 (Columbus, Ohio, U.S.A.), E.M. Gershwin et al, "Identification and specificity of a cDNA encoding the 70kD mitochondrial antigen recognized in primary biliary cirrhosis", see page 180, column 1, abstract no. 18762n, J. Immunol., 1987, 138(10), 3525-31 (Eng.). (1-12)
- X Mendel-Hartvig, I. et al. "Primary biliary cirrhosis: further biochemical and immunological characterization of mitochondrial antigens", Clinical and Experimental Immunology, Volume 62, issued 1985 (Blackwell Scientific Publications, Oxford, England), see pages 371 to 379. (8)
- X Frazer, I.H. et al. "Reactivity of Anti-mitochondrial Autoantibodies in Primary Biliary Cirrhosis : Definition of Two Novel Mitochondrial Polypeptide Antigens", Journal of Immunology, Volume 135, No. 3, issued 1985 September (Williams & Wilkins Co., Baltimore, U.S.A.), see pages 1739 to 1745. (8)

(continued)

* Special categories of cited documents:
 "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
 "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

6 April 1988 (06.04.88)

Date of Mailing of this International Search Report

(11.04.88) 11 APRIL 1988

International Searching Authority

Australian Patent Office

Signature of Authorised Officer

S.D. BARKER

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

- A Alderuccio, F. et al. "Identification and Characterization of Mitochondria Autoantigens in Progressive Systemic Sclerosis : Identity with the 72,000 Dalton Autoantigen in Primary Biliary Cirrhosis", Journal of Immunology, Volume 137, no. 6, issued 1986 September, (Williams & Wilkins Co., Baltimore, U.S.A.), see pages 1855 to 1859.
- A Baum, H. et al. "The PBC-Specific Antigen", Molecular Aspects of Medicine, Volume 8, no. 3, issued 1985 (Pergamon Press, Ltd, Oxford, England), see pages 201 to 234.

(continued)

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:
 1. Claim numbers 13 to 16 because they relate to subject matter not required to be searched by this Authority, namely:

the matter claimed is excluded subject matter, that is, diagnostic methods etc. under Rule 39 of the P.C.T.

2. Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically

3. Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(e).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
 No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	Berg, P.A. et al. "ATPase-Associated Antigen (M2): Marker Antigen for Serological Diagnosis of Primary Biliary Cirrhosis", The Lancet, Volume 2 (8313), issued 1982 December, (Lancet Ltd, London, England), see pages 1423 to 1426.	
A	Sayers, T. et al. "Antimitochondrial Antibodies (AMA) in Primary Biliary Cirrhosis. I. Separation of the PBC Antigen Activity from mitochondrial ATPase Activity", Journal of Bioenergetics and Biomembranes, Volume 13, nos. 5/6, issued 1981, (Plenum Publishing Corp., New York, U.S.A.), see pages 255 to 267.	

WO 88/04689

PCT/AU87/00427

1/11




FIG. 1.

2/11




FIG. 2.




FIG. 3.

SUBSTITUTE SHEET

WO 88/04689

PCT/AU87/00427

3/11



FIG. 4.

SUBSTITUTE SHEET

4/11




FIG. 5.

5/11

Gly Pro Glu Ala Phe Lys Asn Tyr Thr Leu Asp Ser Ala Thr				
GGG CCT GAGG CTT TAAAA ATT ATAC ATT GGATT CAG CAACA				
10	20	30	40	
Pro Ala Ala Pro Ser Ala Ser Ala Pro Gln Ser Ser Tyr Pro				
CCAG CTG CAC CCTT CTG CAAG TGCT CCAG GTAG CTCC TAT CCC				
100	110	120	130	
Gly Thr Val Gln Arg Trp Glu Lys Lys Val Gly Glu Lys Leu				
GG CAC CGT CCAG AGGT GGG AAA AGAA AGT GGG AGAGA AGCT G				
190	200	210	220	
Gly Phe Glu Val Gln Glu Glu Gly Tyr Leu Ala Lys Ile Leu				
GG CTT GAAGT ACA AGA AGA AGGT TAT CTGG CAAA AAT CCTG				
280	290	300	310	
Ile Val Glu Lys Gln Glu Asp Ile Ala Ala Phe Ala Asp Tyr				
ATAG TAG AAA AACAGGA AGA TATAG CAGC ATTG CAG ACT AC				
370	380	390	400	
Pro Pro Pro Val Ala Ala Val Pro Pro Ile Pro Gln Pro Leu				
CCAC CCCC CAGT GG CAG CTG TT CCT CCC ATC CCCC CAG CCT TA				
460	470	480	490	
Val Ser Pro Leu Ala Lys Lys Leu Ala Ala Glu Lys Gly Ile				
GTT AG CCCT CTTG CAA AGAA ATT GGC AGC AGA GAA AGGG ATT				
550	560	570	580	
Lys Asp Ile Asp Ser Phe Val Pro Thr Lys Ala Ala Pro Ala				
AAGG AC ATT GACT CTTT GTGCC TACTA AGG CTG CT C TGCC				
640	650	660	670	

FIG. 6a.

6/11

AlaAlaThrGlnAlaAlaProAlaProAlaAlaAlaProAlaAlaAla
 GCTGCCACACAGGCAGCCCCAGCTGCAGCTCCAGCTGCTGCC
 50 60 70 80 90
 ValHisMetGlnIleValLeuProAlaLeuSerProThrMetThrMet
 GTTCACATGCAGATTGTTCTTCCTGCCCTCTCCCCAACCATGACCATG
 140 150 160 170 180
 SerGluGlyAspLeuLeuAlaGluIleGluThrAspLysAlaThrile
 AGTGAAGGAGACTTGCTGGCAGAGATAGAGACCACAAAGGCCACCATA
 230 240 250 260 270
 ValProGluGlyThrArgAspValProLeuGlyThrProLeuCysIle
 GTCCCTGAAGGCAACAAGGATGTTCTCTGGGAAACCCGCTATGTATC
 320 330 340 350 360
 ArgProThrGluValThrSerLeuLysProGlnAlaProProProVal
 AGGCCAACAGAAGTGACCAAGCTAAAGCCACAGGCACCAACCTGTTC
 410 420 430 440 450
 AlaProThrProSerAlaAlaProAlaGlyProLysGlyArgValPhe
 GCACCTACCCCCCTCAGCCGCTCCTGCTGGACCAAAGGGAAAGGGTGTTC
 500 510 520 530 540
 AspLeuThrGlnValLysGlyThrGlyProGluGlyArgIleIleLys
 GACCTCACCAAGTTAAAGGGACGGGACCCAGAAGGCAGAACATCATCAAG
 590 600 610 620 630
 AlaAlaAlaAlaAlaProProGlyProArgValAlaProThrProAla
 GCTGCAGCAGCTGCTCCCCGGGTCCAAGAGTGGCACCAACTCCTGCA
 680 690 700 710 720

Fig. 6b.

7/11

Gly	Val	Phe	Ile	Asp	Ile	Pro	Ile	Ser	Asn	Ile	Arg	Arg	Val
GGT	GT	CTT	CA	TAG	ACAT	CCCC	CAT	CAG	CAA	CATT	CGTC	GAG	TG
730	740	750	760										
Leu	Ser	Val	Asp	Val	Asn	Met	Gly	Glu	Val	Leu	Leu	Val	Arg
CTT	TCT	GTT	GAT	GTA	AAAT	AT	GGG	GAG	GGT	GCT	GTT	GGT	GCG
820	830	840	850										
Asp	Phe	Ile	Ile	Lys	Ala	Ser	Ala	Leu	Ala	Cys	Leu	Lys	Val
GACT	TTCAT	CATAA	AGCTT	CAG	CTT	GGC	CTG	CCT	GAA	AGTT			
910	920	930	940										
Val	Val	Asp	Val	Ser	Val	Ala	Val	Ser	Thr	Pro	Ala	Gly	Leu
GTGGT	TGAT	GTCAG	CGTT	GCT	GTCAGT	ACCC	CCTGCAGG	ACTT					
1000	1010	1020	1030										
Ala	Ser	Asp	Val	Val	Ser	Leu	Ala	Ser	Lys	Ala	Arg	Glu	Gly
GCTAGT	GATGTT	GTTCTT	CCTT	AGCCT	CCAAAG	CAAG	GCAAG	GAGGGT					
1090	1100	1110	1120										
Leu	Gly	Met	Phe	Gly	Ile	Lys	Asn	Phe	Ser	Ala	Ile	Ile	Asn
TTA	GGG	ATG	TTC	GGAA	ATT	AAGA	ATT	TCT	CTGCG	ATT	TTAAC		
1180	1190	1200	1210										
Ile	Pro	Ala	Asp	Asn	Glu	Lys	Gly	Phe	Asp	Val	Ala	Ser	Val
ATCCC	CTG	CAG	ATA	ATG	GAG	AAAGG	CTT	GAC	GTGG	CTAGT	GTC		
1270	1280	1290	1300										
Leu	Glu	Pro	Ser	Gly	Leu	Leu							
TTGG	GAG	CCC	CAG	TGG	CTT	GCT							
1360	1370												

Fig. 6c.

8//

Ile	Ala	Gln	Arg	Leu	Met	Gln	Ser	Lys	Gln	Thr	Ile	Pro	His	Tyr	Tyr			
ATT	GGG	CAG	AGG	GCT	CAT	GCAG	TGAA	GCAG	ACTA	TAC	CTC	ATT	ATT	AAC	TAC			
770	780	790	800											810				
Lys	Glu	Leu	Asn	Lys	Met	Leu	Glu	Gly	Lys	Gly	Lys	Ile	Ser	Val	Asn			
AAG	GA	CTT	AA	TA	AG	ATG	CTT	GAAG	GTAA	AGG	AAA	ATC	TCC	GTCA	AT			
860	870	880	890											900				
Pro	Glu	Ala	Asn	Ser	Ser	Trp	Met	Asp	Thr	Val	Ile	Arg	Gln	Asn	His			
CCT	GAAG	CAA	ACT	CAT	CTT	GGAT	GGAC	ACAG	TTA	TAC	GA	ACAA	AA	ATC	AT			
950	960	970	980											990				
Ile	Thr	Pro	Ile	Val	Phe	Asn	Ala	His	Ile	Lys	Gly	Leu	Glu	Thr	Ile			
ATC	ACC	CC	CTT	ATT	GTG	TTA	ATG	CAC	AC	ATA	AA	AGG	ACT	GGAA	ACC	ATT		
1040	1050	1060	1070											1080				
Lys	Leu	Gln	Pro	His	Glu	Phe	Gln	Gly	Gly	Thr	Phe	Thr	Ile	Ser	Asn			
AA	ACT	TCA	GCT	CAC	GAG	TTCC	CAG	GGT	GGG	AC	AT	TT	ACA	AT	CTCCA	AC		
1130	1140	1150	1160											1170				
Pro	Pro	Gln	Ala	Cys	Ile	Leu	Ala	Ile	Gly	Ala	Ser	Glu	Asp	Lys	Leu			
CC	AC	CT	CAG	GC	AT	GT	ATT	TT	TGG	CA	AT	GGT	GCT	CC	GAG	GATAA	ACT	G
1220	1230	1240	1250												1260			
Met	Ser	Val	Thr	His	Ser	Ala	Val	Ile	Ile	Glu	Leu	Trp	Met	Glu	Gln			
ATG	TCT	GTC	AC	AC	ACT	CAG	CTG	TGAT	CAT	CGAG	TT	GAT	GG	GAG	CAG			
1310	1320	1330	1340											1350				

Fig. 6d.

SUBSTITUTE SHEET

9/11




FIG. 7.

10/11

Pro Gly Ser Ser Tyr Pro Pro His Met Glu Val Leu Leu Pro Ala
 CCTGGTAGCTCATATCCCC CTCACATGCAGGTACTTCTTCCCTGCC
 10 20 30 40
 Lys Val Glu Glu Lys Leu Ser Glu Glu Asp Leu Leu Ala Glu Ile
 AAAGTGGGTGAGAAGCTAACGTGAAGGGAGACTTACTGGCAAGAGATA
 100 110 120 130
 Tyr Leu Ala Lys Ile Leu Val Pro Glu Gly Thr Arg Asp Val Pro
 TATCTGGCAAAAATCCTGGTCCCTGAAGGCACAAGAGATGTCCCT
 190 200 210 220
 Ser Ala Phe Ala Asp Tyr Arg Pro Thr Glu Val Thr Asp Leu Lys
 TCAGCATTGCTGACTATAGGCCAACCGAAGTAACAGATTTAAAA
 280 290 300 310
 Pro Thr Pro Glu Pro Leu Ala Pro Thr Pro Ser Ala Pro Cys Pro
 CCAACTCCCCAGCCTTAGCTCCTACACCTTCAGCACCTGCCCA
 370 380 390 400
 Ala Lys Lys Leu Ala Val Glu Lys Gly Ile Asp Leu Thr Glu Val
 GCAAAGAAGTTGGCAGTAGAGAAAGGGATTGATCTTACACAAGTA
 460 470 480 490
 Ser Phe Val Pro Ser Lys Val Ala Pro Ala Pro Ala Ala Val Val
 TCTTTGTGCCCTAGTAAAGTTGCTCCTGCTCCGGCAGCTGTTGTG
 550 560 570 580
 Thr Asp Ile Pro Ile Ser Asn Ile Arg Arg Val Ile Ala Glu Arg
 ACAGATATCCCAATCAGCAACATTCTCGTCGGGTTATTGCACAGCGA
 640 650 660 670
 Asp Val Asn Met Glu Val Leu Leu Val Arg Lys Glu Leu Asn
 GATGTAAATATGGGAGAAGTTTGTTGGTACGGAAAGAACTTAAT
 730 740 750 760
 Ile Lys Ala Ser Ala Leu Ala Cys Leu Lys Val Pro Glu Ala Asn
 ATAAGCTTCAGCTTGGCATGTTAAAAGTTCCCAGCAAGCAAAT
 820 830 840 850
 Val Ser Val Ala Val Ser Thr Pro Ala Gly Leu Ile Thr Pro Ile
 GTCAAGTGTGCGGTCACTCCTGCAGGACTCATCACACCTATT
 910 920 930 940

Fig. 8a.

///

LeuSerProThrMetThrMetGlyThrValGlnArgTrpGluLys					
CTCTCTCCCCACCATGACCATGGGCACAGTCAGAGATGGGAAAAAA	50	60	70	80	90
GlutThrAspLysAlaThrIleGlyPheGluValGlnGluGluGly					
GAAACTGACAAAGCCACTATAGGTTTGAAAGTACAGGAAGAAGGT	140	150	160	170	180
LeuGlyThrProLeuCysIleIleValGluLysGluAlaAspIle					
CTAGGAACCCCACTCTGTATCATTGTAGAAAAAGAGGGCAGATATA	230	240	250	260	270
ProGlnValProProProThrProProProValAlaAlaValPro					
CCACAAGTGCCACCACTACCCCCACCCCCCGGTGGGCCGCTGTTCT	320	330	340	350	360
AlaThrProAlaGlyProLysGlyArgValPheValSerProLeu					
GCTACTCCTGCTGGACCAAAGGGAAAGGGTGTGTAGCCCTCTT	410	420	430	440	450
LysGlyThrGlyProAspGlyArgIleThrLysLysAspIleAsp					
AAAGGGACAGGACCCAGATGGTAGAACATACCAAGAAGGGATATCGAC	500	510	520	530	540
ProProThrGlyProGlyMetAlaProValProThrGlyValPhe					
CCTCCCCACAGGTCTGGAAATGGCACCAAGTTCTACAGGTGTCTTC	590	600	610	620	630
LeuMetGlnSerLysGlnThrIleProHisTyrTyrLeuSerIle					
TTAATGCAATCAAAGCAAACCATACCTCATTATTACCTTTCTATC	680	690	700	710	720
LysIleLeuGluGlyArgSerLysIleSerValAsnAspPheIle					
AAGATATTAGAAGGGAGAAGCAAAATTCTGTCAATGACTTCATC	770	780	790	800	810
SerSerTrpMetAspThrValIleArgGlnAsnHisValValAsp					
TCTTCTGGATGGACACAGTTATAAGACAAAATCATGTTGTTGAT	860	870	880	890	900
ValPheAsnAlaHisIleLys					
GTGTTTAATGCACATATAAAA	950	960			

FIG. 8D.